Α,N,N-Trimethyltryptamine

α,N,N-Trimethyltryptamine, also known as α-methyl-N,N-dimethyltryptamine or as Alpha-N, is a psychedelic drug of the tryptamine and α-alkyltryptamine families. It is similar in chemical structure to other psychedelic tryptamines such as N,N-dimethyltryptamine (DMT) and α-methyltryptamine (αMT). It is taken orally.

Use and effects

α,N,N-TMT was briefly mentioned by Alexander Shulgin in his 1997 book TiHKAL (Tryptamines I Have Known and Loved), but he did not mention having tested it and did not describe its effects, dose, or duration. ==Interactions==

Pharmacology

Pharmacodynamics The drug has been tested in animals and compared with α-methyltryptamine (αMT). It was found to produce similar effects as αMT, such as hyperlocomotion and reversal of reserpine-induced behavioral depression, but with only around half the potency of αMT. ==Chemistry==

Chemistry

Analogues Analogues of α,N,N-TMT (N,N-dimethyl-AMT) include α-methyltryptamine (AMT), α,N-DMT (N-methyl-AMT), α-methylserotonin (AMS; 5-HO-AMT), 5-MeO-AMT (α,O-DMS), α,N,O-TMS (N-methyl-5-MeO-AMT), and α,N,N,O-TeMS (N,N-dimethyl-5-MeO-AMT), among others. ==History==

History

α,N,N-TMT was encountered as a novel designer drug in Europe by 2015. ==Society and culture==

Society and culture

Legal status Canada α,N,N-TMT is not an explicitly nor implicitly controlled substance in Canada as of 2025. United States α,N,N-TMT is not an explicitly controlled substance in the United States. However, it could be considered a controlled substance under the Federal Analogue Act if intended for human consumption. ==See also==

Source: Wikipedia ↗

tickerdossier.com tickerdossier.substack.com